{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T03:04:25Z","timestamp":1790564665552,"version":"4.1.0"},"reference-count":31,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Rituximab plus cyclophosphamide-doxorubicin-vincristine-prednisone (R-CHOP) is the standard of care for untreated diffuse large B-cell lymphoma (DLBCL). However, the schedule for rituximab administration has not been optimized. To compare standard R-CHOP with CHOP plus dose-dense weekly rituximab (RW-CHOP) in patients with untreated DLBCL, we conducted a phase 2\/3 study (JCOG0601, jRCTs031180139). Patients were randomly assigned to R-CHOP (CHOP-21 with 8 doses of rituximab once every 3 weeks [375 mg\/m2]) or RW-CHOP (CHOP-21 with 8 doses of weekly rituximab [375 mg\/m2]) groups. The primary end point of the phase 2 component was percent complete response (%CR) of the RW-CHOP arm, whereas that of the phase 3 component was progression-free survival (PFS). Between December 2007 and December 2014, 421 untreated patients were randomly assigned to R-CHOP (213 patients) or RW-CHOP (208 patients). The %CR in the RW-CHOP arm was 85.3% and therefore met the prespecified decision criteria for the phase 2 component. With a median follow-up of 63.4 months, the 3-year PFS and overall survival were 79.2% and 88.7% in the R-CHOP arm and 80.3% and 90.4% in the RW-CHOP arm, respectively. There was no significant difference in PFS (hazard ratio, 0.95; 90.6% confidence interval, 0.68-1.31). Although the safety profile and efficacy of RW-CHOP was comparable with R-CHOP and its tolerability was acceptable, weekly rituximab in combination with CHOP during the early treatment period did not improve PFS in untreated patients with DLBCL. This trial was registered at jrct.niph.go.jp as #jRCTs031180139.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020002567","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T06:10:31Z","timestamp":1613715031000},"page":"984-993","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["A randomized phase 2\/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5530-818X","authenticated-orcid":false,"given":"Ken","family":"Ohmachi","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Tokai University School of Medicine, Kanagawa, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Aichi, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[{"name":"Department of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gakuto","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Japan Clinical Oncology Group Data Center\/Operations Office, National Cancer Center Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Mizutani","sequence":"additional","affiliation":[{"name":"Japan Clinical Oncology Group Data Center\/Operations Office, National Cancer Center Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital East, Chiba, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2682-2179","authenticated-orcid":false,"given":"Noriko","family":"Fukuhara","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tohoku University Hospital, Miyagi, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Japanese Red Cross Nagoya Daini Hospital, Aichi, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8588-8955","authenticated-orcid":false,"given":"Kazuhito","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Aichi, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Mie University Graduate School of Medicine, Mie, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Tsukamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Gunma University Hospital, Gunma, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4951-960X","authenticated-orcid":false,"given":"Shinsuke","family":"Iida","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Utsumi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shiga General Hospital, Shiga, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5234-0507","authenticated-orcid":false,"given":"Isao","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Hematologic Oncology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Imaizumi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Tokunaga","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Nagoya Medical Center, Aichi, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5658-3765","authenticated-orcid":false,"given":"Yasufumi","family":"Masaki","sequence":"additional","affiliation":[{"name":"Department of Hematology and Immunology, Medicine, Kanazawa Medical University, Ishikawa, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Murayama","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hyogo Cancer Center, Hyogo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Yakushijin","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Ehime University Graduate School of Medicine, Ehime, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youko","family":"Suehiro","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6682-2451","authenticated-orcid":false,"given":"Kisato","family":"Nosaka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Dobashi","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology and Hematology, The Jikei University Daisan Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Kuroda","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4246-9969","authenticated-orcid":false,"given":"Yasushi","family":"Takamatsu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hematology and Infectious Diseases, Fukuoka University Hospital, Fukuoka, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0654-6920","authenticated-orcid":false,"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Tokai University School of Medicine, Kanagawa, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Ishizawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tohoku University Hospital, Miyagi, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6853-4688","authenticated-orcid":false,"given":"Michinori","family":"Ogura","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Japanese Red Cross Nagoya Daini Hospital, Aichi, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Yoshino","sequence":"additional","affiliation":[{"name":"Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomitsu","family":"Hotta","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Nagoya Medical Center, Aichi, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Tsukasaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital East, Chiba, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Nagai","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Nagoya Medical Center, Aichi, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Japan Clinical Oncology Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"issue":"5","key":"2021021616333130100_B1","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30935-5","article-title":"Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial","volume":"20","author":"Davies","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9880","key":"2021021616333130100_B2","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","article-title":"Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles","volume":"381","author":"Cunningham","year":"2013","journal-title":"Lancet"},{"issue":"21","key":"2021021616333130100_B3","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance\/CALGB 50303","volume":"37","author":"Bartlett","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"2021021616333130100_B4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/bmt.2015.213","article-title":"Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study","volume":"51","author":"Van Den Neste","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2021021616333130100_B5","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/bmt.2016.213","article-title":"Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study","volume":"52","author":"Van Den Neste","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2021021616333130100_B6","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/bjh.14453","article-title":"Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era","volume":"176","author":"Vardhana","year":"2017","journal-title":"Br J Haematol"},{"issue":"16","key":"2021021616333130100_B7","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study [published correction in Blood. 2018;131(5):587-588]","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2021021616333130100_B8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"5","key":"2021021616333130100_B9","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"issue":"8","key":"2021021616333130100_B10","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"issue":"6","key":"2021021616333130100_B11","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"issue":"5","key":"2021021616333130100_B12","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/annonc\/mdh176","article-title":"Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma","volume":"15","author":"Tobinai","year":"2004","journal-title":"Ann Oncol"},{"issue":"6","key":"2021021616333130100_B13","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/annonc\/mdf155","article-title":"Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study","volume":"13","author":"Igarashi","year":"2002","journal-title":"Ann Oncol"},{"issue":"9","key":"2021021616333130100_B14","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","article-title":"Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin\u2019s lymphoma","volume":"9","author":"Berinstein","year":"1998","journal-title":"Ann Oncol"},{"issue":"5","key":"2021021616333130100_B15","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood.V97.5.1392","article-title":"Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin","volume":"97","author":"Ghetie","year":"2001","journal-title":"Blood"},{"issue":"5","key":"2021021616333130100_B16","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1200\/JCO.1994.12.5.1074","article-title":"Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin\u2019s lymphoma: a literature review","volume":"12","author":"Haw","year":"1994","journal-title":"J Clin Oncol"},{"issue":"27","key":"2021021616333130100_B17","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021021616333130100_B18","volume-title":"World Health Organization classification of tumors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues","author":"Jaffe","year":"2001"},{"issue":"14","key":"2021021616333130100_B19","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N Engl J Med"},{"issue":"5","key":"2021021616333130100_B20","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"31","key":"2021021616333130100_B21","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"2021021616333130100_B22","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3109\/10428194.2012.691482","article-title":"Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi\/Grupo de Estudos em Mol\u00e9stias Onco-Hematol\u00f3gicas retrospective study","volume":"54","author":"Carella","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2021021616333130100_B23","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1111\/bjh.15927","article-title":"Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R-CHOP","volume":"186","author":"Eyre","year":"2019","journal-title":"Br J Haematol"},{"issue":"14","key":"2021021616333130100_B24","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2011-09-380949","article-title":"The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL","volume":"119","author":"M\u00fcller","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2021021616333130100_B25","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/blood-2013-07-517037","article-title":"Suboptimal dosing of rituximab in male and female patients with DLBCL","volume":"123","author":"Pfreundschuh","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2021021616333130100_B26","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/annonc\/mdu208","article-title":"Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL","volume":"25","author":"Murawski","year":"2014","journal-title":"Ann Oncol"},{"issue":"3","key":"2021021616333130100_B27","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14860","article-title":"Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients","volume":"179","author":"Pfreundschuh","year":"2017","journal-title":"Br J Haematol"},{"issue":"36","key":"2021021616333130100_B28","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1200\/JCO.2013.54.6861","article-title":"Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group [published correction in J Clin Oncol. 2015;33(17):1991]","volume":"32","author":"Pfreundschuh","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"2021021616333130100_B29","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood-2014-06-584623","article-title":"Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313","volume":"125","author":"Persky","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2021021616333130100_B30","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol"},{"issue":"15","key":"2021021616333130100_B31","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/4\/984\/1800517\/advancesadv2020002567.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/4\/984\/1800517\/advancesadv2020002567.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T06:10:56Z","timestamp":1613715056000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/4\/984\/475201\/A-randomized-phase-2-3-study-of-R-CHOP-vs-CHOP"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,2,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020002567","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,16]]}}}